14 completed, 6 terminated, 1 withdrawn. 10 Phase 1, 7 Phase 2, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 10 | Completed 8, Terminated 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 5, Terminated 2 |
| Phase 3 | 5 | Terminated 4, Completed 1 |
Follow LY 2140023: new trials by email Literature Review of LY 2140023 trials Research Report on LY 2140023
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Glutamate Reducing Interventions in Schizophrenia Pomaglumetad methionil - Clinical High Risk for Psychosis | Phase 1 | Completed | New York State Psychiatric Institute | 16 | 2018-04-17 | 2021-12-01 |
| A mGlu2/3 Agonist in the Treatment of PTSD Pomaglumetad Methionil 160mg, Pomaglumetad Methionil 40mg, Placebo - Post-traumatic Stress Disorder | Phase 1 | Terminated | NYU Langone Health | 10 | 2014-09-01 | 2018-11-02 |
| A Study of LY2140023 in Healthy Participants LY2140023 - Healthy Participants | Phase 1 | Withdrawn | Denovo Biopharma LLC | 2012-08-01 | 2021-08-23 | |
| A Study of LY2140023 in Healthy Participants LY2140023, 14C-LY2140023, 14C-LY404039 - Healthy Participants | Phase 1 | Completed | Denovo Biopharma LLC | 18 | 2012-07-01 | 2021-09-21 |
| A Study of LY2140023 in Healthy Participants LY2140023, Aqueous activated charcoal - Healthy Volunteer Study | Phase 1 | Completed | Denovo Biopharma LLC | 27 | 2012-06-01 | 2021-09-21 |
| A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia LY2140023, Placebo, Moxifloxacin - Schizophrenic Disorders | Phase 1 | Completed | Denovo Biopharma LLC | 86 | 2012-06-01 | 2023-04-03 |
| A Study of LY2979165 and LY2140023 in Healthy Volunteers LY2979165, LY2140023, Placebo - Healthy Volunteers | Phase 1 | Completed | Eli Lilly and Company | 52 | 2012-04-01 | 2013-08-02 |
| A Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia Pomaglumetad methionil - Schizophrenia | Phase 3 | Terminated | Denovo Biopharma LLC | 129 | 2011-12-01 | 2026-09-14 |
| A Study of LY2140023 in Hepatically-Impaired Participants LY2140023 - Hepatic Insufficiency | Phase 1 | Completed | Denovo Biopharma LLC | 37 | 2011-11-01 | 2021-09-22 |
| A Physical Dependence Study in Schizophrenia LY2140023, Placebo - Schizophrenia | Phase 3 | Completed | Denovo Biopharma LLC | 123 | 2011-11-01 | 2022-09-14 |
| The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects Ammonium Chloride + LY2140023, Sodium Bicarbonate + LY2140023, LY2140023 - Healthy Subjects | Phase 1 | Completed | Denovo Biopharma LLC | 29 | 2011-09-01 | 2026-09-15 |
| A Study of Safety and Tolerability in Subjects With Schizophrenia LY2140023, Aripiprazole - Schizophrenia | Phase 1 | Completed | Denovo Biopharma LLC | 75 | 2011-05-01 | 2022-09-14 |
| A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients LY2140023, Aripiprazole - Schizophrenia | Phase 3 | Terminated | Denovo Biopharma LLC | 678 | 2011-04-01 | 2022-09-07 |
| A Study of LY2140023 in Patients With Schizophrenia LY2140023, Placebo - Schizophrenia | Phase 3 | Terminated | Denovo Biopharma LLC | 567 | 2011-03-01 | 2022-10-18 |
| A Long-Term, Open-Label, Study on Schizophrenia LY2140023, Olanzapine, Aripiprazole - Schizophrenia | Phase 2 / Phase 3 | Terminated | Denovo Biopharma LLC | 560 | 2010-06-01 | 2026-09-14 |
| A Study in Schizophrenic Patients LY2140023, Placebo - Schizophrenia | Phase 2 | Terminated | Denovo Biopharma LLC | 82 | 2010-05-01 | 2021-09-14 |
| A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients Risperidone, Placebo, LY2140023 - Schizophrenia | Phase 2 | Completed | Denovo Biopharma LLC | 1134 | 2010-03-01 | 2026-09-14 |
| A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms LY2140023, Placebo, Standard of Care - Schizophrenia | Phase 2 | Completed | Denovo Biopharma LLC | 167 | 2010-01-01 | 2022-09-07 |
| A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients LY2140023, aripiprazole, olanzapine - Schizophrenia | Phase 2 | Completed | Denovo Biopharma LLC | 261 | 2009-03-01 | 2022-11-08 |
| A Study for Participants With Schizophrenia LY2140023, Olanzapine, Placebo - Schizophrenia | Phase 2 | Completed | Denovo Biopharma LLC | 669 | 2007-09-01 | 2026-09-14 |
Showing 20 of 21. Sign in to see all of them.
Schizophrenia (13) · Hepatic Insufficiency (1) · Stress Disorders, Post-Traumatic (1)
Denovo Biopharma LLC (18) · Eli Lilly and Company (1) · NYU Langone Health (1) · New York State Psychiatric Institute (1)
United States (11) · Russia (6) · Germany (5) · Mexico (4) · Puerto Rico (4) · United Kingdom (4) · Austria (3) · Croatia (3) · Romania (3) · Spain (3) · France (2) · Greece (2) · Japan (2) · Poland (2) · South Korea (2)
Charles Marmar, MD (1) · Scott Small, MD (1)
PMID 25890643, PMID 24772351, PMID 25006819, PMID 25539791
R61MH112800 (1)